Palatin investor relations material

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The Company's lead product candidate is bremelanotide, which is under review by the U.S. Food and Drug Administration (FDA) for the potential treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women; and the treatment of benign prostatic hyperplasia (BPH) in men. The Company has its U.S.-based headquarters and research facility located in Cranbury, New Jersey.